{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/GOVXW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GOVXW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","market":"US","secType":"STK","nameCN":"GeoVax Labs Inc","latestPrice":0.03,"timestamp":1745438400000,"preClose":0.0302,"halted":0,"volume":30450,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-Mkt","change":-0.0002,"latestTime":"04-24 06:11:52 EDT","open":0.0302,"high":0.0302,"low":0.03,"amount":913.9432,"amplitude":0.006623,"askPrice":0,"askSize":0,"bidPrice":0.0272,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745501400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.03,"volumeRatio":2.9201350150748593},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GOVXW\",,,,,undefined,":{"symbol":"GOVXW","floatShares":0,"roa":"-180.23%","roe":"-462.31%","lyrEps":0,"volumeRatio":2.9201350150748593,"shares":0,"dividePrice":0,"high":0.0302,"amplitude":0.006623,"preClose":0.0302,"low":0.03,"week52Low":0.0268,"pbRate":"0.00","psRate":"0.00","week52High":0.65,"institutionHeld":0,"latestPrice":0.03,"committee":1,"eps":0,"divideRate":0,"volume":30450,"delay":0,"ttmEps":0,"open":0.0302,"prevYearClose":0.1001,"prevWeekClose":0.0331,"prevMonthClose":0.0502,"prevQuarterClose":0.0502,"fiveDayClose":0.0331,"twentyDayClose":0.0725,"sixtyDayClose":0.1044},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/GOVXW\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GOVXW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529588411","title":"GeoVax Appoints Dr. Senthil Ranganathan as Vice President, Technical Development and CMC Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2529588411","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529588411?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:00","pubTimestamp":1745326800,"startTime":"0","endTime":"0","summary":"Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities. ATLANTA, GA - April 22, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced the appointment of Senthil Ranganathan, Ph.D. as Vice President, Technical Development and CMC Operations. Dr. Ranganathan brings over 20 years of experience in biologics development to commercialization across vaccines, cell and gene therapies, monoclonal antibodies, and viral vector products.GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as  a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient po","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-appoints-dr-senthil-ranganathan-130000832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVX","BK4006","LU0170899867.USD","IE00BHPRN162.USD","IE00BKVL7J92.USD","LU1363072403.SGD","IE00BZ1G4Q59.USD","LU0267386448.USD","LU0882574139.USD","IE00B1BXHZ80.USD","BK4022","LU0149725797.USD","LU0971096721.USD","CMC","GOVXW","R","BK4232"],"gpt_icon":0},{"id":"2527241430","title":"GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2527241430","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527241430?lang=en_us&edition=fundamental","pubTime":"2025-04-16 22:15","pubTimestamp":1744812923,"startTime":"0","endTime":"0","summary":"D. Boral Capital lowered the firm’s price target on GeoVax Labs  to $14 from $18 and keeps a Buy rating on the shares. GeoVax has encountered a significant challenge following the termination of its BARDA-funded Phase 2b clinical trial for the GEO-CM04S1 COVID-19 vaccine, the firm says. This decision, made for the government’s convenience, halts a pivotal study that was set to evaluate GEO-CM04S1 against an approved mRNA vaccine in a 10,000-participant trial under Project NextGen. The abrupt termination raises concerns about the future trajectory of GeoVax’s vaccine development efforts and its financial implications, says D. Boral Capital. The firm has removed all BARDA revenues and stockpile awards that were in its model.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.GeoVax Labs price target lowered to $8.50 from $15 at Alliance Global Partners. GeoVax","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/geovax-labs-price-target-lowered-141523619.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-labs-price-target-lowered-141523619.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOVXW","GOVX"],"gpt_icon":0},{"id":"2527424145","title":"GeoVax Provides Update on BARDA Project NextGen and Outlines 2025 Business Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2527424145","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527424145?lang=en_us&edition=fundamental","pubTime":"2025-04-16 21:00","pubTimestamp":1744808400,"startTime":"0","endTime":"0","summary":"Company Reaffirms Commitment to Innovation in COVID-19, Oncology, and Biosecurity Amid Strategic Program Developments. ATLANTA, GA - April 16, 2025  - GeoVax Labs, Inc. , a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today addressed the termination of its Project NextGen  award by the Biomedical Advanced Research and Development Authority , effective April 11, 2025. The Company also provided a comprehensive business update across its core programs, including the next-generation COVID-19 vaccine , cancer immunotherapy , Mpox/smallpox vaccine , and advanced MVA manufacturing process.GeoVax expressed disappointment in the HHS/BARDA action but remains committed to the critical medical need addressed by GEO-CM04S1, particularly among the more than 40 million immunocompromised Americans - and over 400 million people globally - who remain inadequately protected by the current authorized COVID-19 vaccines. Thus far, clinical ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-provides-barda-project-nextgen-130000111.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","NGCAU","BK4232","BNTX","GOVX","BK4548","BK4139","BK4551","R","BK4585","GOVXW","BK4588","BK4022","BK4535"],"gpt_icon":0},{"id":"2527941465","title":"GeoVax to Present Clinical Data at Upcoming April Industry Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2527941465","media":"NewMediaWire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527941465?lang=en_us&edition=fundamental","pubTime":"2025-04-15 21:00","pubTimestamp":1744722000,"startTime":"0","endTime":"0","summary":"Data to be Presented on the Company's GEO-CM04S1 and Gedeptin Programs. ATLANTA, GA - April 15, 2025  - GeoVax Labs, Inc. , a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that members of its senior management team and other scientific representatives will participate in two upcoming industry events during April. Event details are as follows:. World Vaccine Congress, April 22-24, 2025, Washington, DC. Phase 2b Study Results That Evaluated and Compared GeoVax's Multi-Antigen, Vaccine Candidate  to an Approved Vaccine Against COVID-19. Don J. Diamond, PhD, Director, Division of Vaccine Research & Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center. Viral-Vectored, Gene-Directed Prodrug Therapy  in Needle-Accessible Solid Tumors","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/geovax-present-clinical-data-upcoming-130000897.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","BK4022","BK4568","BK4583","GOVXW","BK4535","BK4548","BK4551","BK4139","GOVX","BK4588","R","BNTX","BK4232"],"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GOVXW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2022-08-03","symbol":"GOVXW","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659499200000,"reportTimeType":"post","actualEps":null},{"date":"2022-04-27","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1651089600000,"name":null,"time":"Post Market","dateTimestamp":1651032000000,"actualEps":null},{"date":"2022-03-09","symbol":"GOVXW","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1646859600000,"name":null,"time":"Post Market","dateTimestamp":1646802000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GOVXW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GOVXW\",market:\"US\",delay:false,,,undefined,":{}}}